Race and sex differences in the initiation of diabetes drugs by privately insured US adults

Rozalina G. McCoy; Holly K. Van Houten; Shannon M. Dunlay; Xiaoxi Yao; Timothy Dempsey; Peter A. Noseworthy; Lindsey R. Sangaralingham; Andrew H. Limper; Nilay D. Shah

doi:10.1007/s12020-021-02710-4

Race and sex differences in the initiation of diabetes drugs by privately insured US adults

Rozalina G. McCoy, Holly K. Van Houten, Shannon M. Dunlay, Xiaoxi Yao, Timothy Dempsey, Peter A. Noseworthy, Lindsey R. Sangaralingham, Andrew H. Limper, Nilay D. Shah

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	480-484
Number of pages	5
Journal	Endocrine
Volume	73
Issue number	2
DOIs	https://doi.org/10.1007/s12020-021-02710-4
State	Published - Aug 2021

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1007/s12020-021-02710-4

Cite this

@article{b34fe79011ce4a58b4d70dd618c05780,

title = "Race and sex differences in the initiation of diabetes drugs by privately insured US adults",

author = "McCoy, {Rozalina G.} and {Van Houten}, {Holly K.} and Dunlay, {Shannon M.} and Xiaoxi Yao and Timothy Dempsey and Noseworthy, {Peter A.} and Sangaralingham, {Lindsey R.} and Limper, {Andrew H.} and Shah, {Nilay D.}",

note = "Funding Information: The authors have no competing interests to declare. In the past 36 months, R.G.M. also received support from an AARP Quality Measure Innovation Grant and the NIDDK (P30DK111024). In the past 36 months, N.D.S. has received research support through Mayo Clinic from the Food and Drug Administration (FDA) to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the AHRQ (R01HS025164; R01HS025402; R03HS025517); the National Heart, Lung and Blood Institute of the NIH (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet). S.M.D. receives research support from the NIH (R01HL144529, R03HL135225, T32HL07111) and the FDA (U01FD005938). P.A.N. receives funding from NIH (R01AG062436-01A1, R21HL140205, R01HL131535, R01HS25402, R01HL143070) FDA (U01FD05938) and the American Heart Association (18SFRN34230146). A.H.L. receives research support from the NIH (R01HL62150) and the Caerus Foundation and Three Lakes Partners Foundation. X.Y. receives funding from NIH (R01AG062436, R21HL140205, R01HS025402) and FDA (U01FD005938). {\textregistered} Funding Information: This effort was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) Grant K23DK114497 (R.G.M.) and the Agency for Healthcare Research and Quality (AHRQ) Comparative Health System Performance Initiative Grant 1U19HS024075 (N.D.S.). Study contents are the sole responsibility of the authors and do not necessarily represent the official views of NIH. ",

year = "2021",

month = aug,

doi = "10.1007/s12020-021-02710-4",

language = "English (US)",

volume = "73",

pages = "480--484",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Humana Press",

number = "2",

}

TY - JOUR

T1 - Race and sex differences in the initiation of diabetes drugs by privately insured US adults

AU - McCoy, Rozalina G.

AU - Van Houten, Holly K.

AU - Dunlay, Shannon M.

AU - Yao, Xiaoxi

AU - Dempsey, Timothy

AU - Noseworthy, Peter A.

AU - Sangaralingham, Lindsey R.

AU - Limper, Andrew H.

AU - Shah, Nilay D.

N1 - Funding Information: The authors have no competing interests to declare. In the past 36 months, R.G.M. also received support from an AARP Quality Measure Innovation Grant and the NIDDK (P30DK111024). In the past 36 months, N.D.S. has received research support through Mayo Clinic from the Food and Drug Administration (FDA) to establish Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938); the Centers of Medicare and Medicaid Innovation under the Transforming Clinical Practice Initiative (TCPI); the AHRQ (R01HS025164; R01HS025402; R03HS025517); the National Heart, Lung and Blood Institute of the NIH (R56HL130496; R01HL131535); the National Science Foundation; and the Patient Centered Outcomes Research Institute (PCORI) to develop a Clinical Data Research Network (LHSNet). S.M.D. receives research support from the NIH (R01HL144529, R03HL135225, T32HL07111) and the FDA (U01FD005938). P.A.N. receives funding from NIH (R01AG062436-01A1, R21HL140205, R01HL131535, R01HS25402, R01HL143070) FDA (U01FD05938) and the American Heart Association (18SFRN34230146). A.H.L. receives research support from the NIH (R01HL62150) and the Caerus Foundation and Three Lakes Partners Foundation. X.Y. receives funding from NIH (R01AG062436, R21HL140205, R01HS025402) and FDA (U01FD005938). ® Funding Information: This effort was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) Grant K23DK114497 (R.G.M.) and the Agency for Healthcare Research and Quality (AHRQ) Comparative Health System Performance Initiative Grant 1U19HS024075 (N.D.S.). Study contents are the sole responsibility of the authors and do not necessarily represent the official views of NIH.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85104074532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104074532&partnerID=8YFLogxK

U2 - 10.1007/s12020-021-02710-4

DO - 10.1007/s12020-021-02710-4

M3 - Comment/debate

C2 - 33830439

AN - SCOPUS:85104074532

SN - 1355-008X

VL - 73

SP - 480

EP - 484

JO - Endocrine

JF - Endocrine

IS - 2

ER -

Race and sex differences in the initiation of diabetes drugs by privately insured US adults

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this